DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.56 USD | -3.41% |
|
-7.49% | -27.49% |
| Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
| Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 65.76M | Sales 2025 * | 121M | Capitalization | 2.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -411M | Net income 2025 * | -442M | EV / Sales 2024 * | 13.5 x |
| Net cash position 2024 * | 1.41B | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 9.29 x |
| P/E ratio 2024 * |
-6.16
x | P/E ratio 2025 * |
-6.1
x | Employees | 445 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +0.75% | ||
| 1 week | -7.09% | ||
| Current month | -21.49% | ||
| 1 month | -17.89% | ||
| 3 months | -5.79% | ||
| 6 months | -13.85% | ||
| Current year | -24.93% |
1 week
15.48
16.95
1 month
15.4821.04
Current year
15.4823.52
1 year
15.4533.31
3 years
15.4579.70
5 years
12.3993.94
10 years
12.3293.94
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | 0.00% | - | |
| 0.31% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 15.56 | -3.41% | 840 796 |
| 24-04-23 | 16.11 | +0.75% | 1,080,081 |
| 24-04-22 | 15.99 | -0.06% | 3,056,993 |
| 24-04-19 | 16 | -3.61% | 1,479,992 |
| 24-04-18 | 16.6 | -1.31% | 1,189,747 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
16.11
USD
Average target price
40.27
USD
Spread / Average Target
+149.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.93% | 2.3B | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +2.97% | 22.19B | |
| -16.16% | 21.33B | |
| -7.26% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- DNLI Stock
